Bruker Co. (NASDAQ:BRKR) Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC grew its position in shares of Bruker Co. (NASDAQ:BRKR) by 15.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 40,522 shares of the medical research company’s stock after purchasing an additional 5,523 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Bruker were worth $2,798,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of BRKR. US Bancorp DE increased its position in shares of Bruker by 12.4% during the 1st quarter. US Bancorp DE now owns 23,443 shares of the medical research company’s stock valued at $2,202,000 after purchasing an additional 2,588 shares during the period. ProShare Advisors LLC raised its position in shares of Bruker by 4.1% during the first quarter. ProShare Advisors LLC now owns 7,065 shares of the medical research company’s stock worth $664,000 after purchasing an additional 280 shares during the period. Entropy Technologies LP acquired a new stake in shares of Bruker during the first quarter worth $612,000. State Board of Administration of Florida Retirement System raised its position in shares of Bruker by 3.5% during the first quarter. State Board of Administration of Florida Retirement System now owns 106,174 shares of the medical research company’s stock worth $9,974,000 after purchasing an additional 3,593 shares during the period. Finally, Orion Portfolio Solutions LLC raised its position in shares of Bruker by 93.7% during the first quarter. Orion Portfolio Solutions LLC now owns 50,522 shares of the medical research company’s stock worth $4,746,000 after purchasing an additional 24,445 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BRKR shares. Wells Fargo & Company cut their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Citigroup cut their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. TD Cowen cut their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Finally, Barclays dropped their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.36.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $55.92 on Thursday. The business’s 50-day moving average price is $63.07 and its two-hundred day moving average price is $65.69. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker Co. has a one year low of $54.55 and a one year high of $94.86. The company has a market capitalization of $8.48 billion, a P/E ratio of 26.88, a price-to-earnings-growth ratio of 2.68 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.74 EPS. Analysts anticipate that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.